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Dear Editors, 
 
Cannabis use is considered a component cause of psychotic disorder interacting with genetic 
and environmental risk factors in increasing psychosis risk (Henquet et al., 2008). Recently, two 
cross-sectional and one prospective study provided evidence that cannabis use interacts additively 
with trauma to increase psychosis risk (Harley et al., 2010; Houston et al., 2008; Konings et al., in 
press). In an attempt at further replication, we examined prospective data from the German Early 
Developmental Stages of Psychopathology (EDSP) study (Lieb et al., 2000; Wittchen et al., 
1998b).  
The EDSP study collected data on the prevalence, incidence, risk factors, comorbidity, and 
course of mental disorders in a random, representative population sample of adolescents and 
young adults in the general population (Lieb, et al., 2000; Wittchen, et al., 1998b). Individuals 
were assessed three times (at T0, T2, and T3) over a 10-year follow-up period. More details on 
the sampling, representativeness, instruments, procedures, and statistical methods of the EDSP 
Study sample have been presented elsewhere (Lieb, et al., 2000; Wittchen, et al., 1998b). Data on 
psychotic symptoms, cannabis use and trauma were acquired with the computerized version of 
the Munich-Composite International Diagnostic Interview (DIA-X/M-CIDI) (Wittchen et al., 
1998a), an updated version of the World Health Organization’s CIDI version 1.2 (Robins et al., 
1988). At T0, the DIA-X/M-CIDI lifetime version was used. At each of the follow-up 
assessments, participants applied the interval version, covering the period of assessment from the 
last interview until the next. Data on positive psychotic symptoms were collected at T2 (lifetime 
version, representing lifetime experience of symptoms) and T3 (interval version, representing 
symptoms that occurred over the T2-T3 period). Presence of positive psychotic experiences was 
broadly defined as any rating of ‘present’ on any of the DIAX/M-CIDI core psychosis items. All 
items were dichotomously rated as ‘absent’ or ‘present’. Cannabis use was assessed at all three 
assessments. Conform previous analyses (Kuepper et al., 2011), cannabis use at T0 was defined 
as lifetime use of cannabis of five times or more and cannabis use at T2 was defined as use of 
cannabis of five times or more since T0. Trauma was assessed at T0 and was dichotomously 
defined as having experienced any of the following events at least once lifetime: war experiences, 
physical threats or attacks, rape, sexual abuse, natural disasters, serious accidents, kidnapping and 
hostage-taking, and witnessing any of the aforementioned events. 
Data were analyzed using STATA, release 11.1 (StataCorp, College Station, TX). Associations 
were expressed as odds ratios (OR) derived from logistic regression models. Interaction between 
T2 cannabis use and trauma was calculated under an additive model (Darroch, 1997), using the 
BINREG procedure in STATA yielding risk differences (RD), followed by calculation of the 
appropriate linear combinations from the model with the interaction, using the STATA LINCOM 
command. To ensure prediction of strictly incident psychotic symptoms over the T2-T3 follow-up 
period, all individuals who had reported lifetime psychotic experiences at T2 were excluded from 
the analyses. Analyses were adjusted for the following confounding risk factors: age (in years), 
sex (0=female, 1=male), socio-economic status (lower, middle, upper, other), cannabis use at 
baseline, use of other drugs at baseline (including psychostimulants, sedatives, opiates, cocaine, 
phencyclidine and psychedelic drugs), and urbanicity, defined dichotomously as living in the city 
of Munich (‘urban’, 4061 persons per square mile) or in the rural surroundings (‘rural’, 553 
persons per square mile) at the time of inclusion.  
We analyzed data of 1923 individuals of which 926 (48.2%) were men. Mean age was 18.3 
years (SD = 3.3 years) at T0, 21.8 (SD = 3.4 years) at T2 and 26.6 (SD = 3.5 years) at T3. There 
was no evidence that trauma moderated the association between T2 cannabis use and incident 
psychotic symptoms over the T2-T3 period (see table 1 for statistics). The interaction remained 
small and non-significant when examining a more stringent outcome criterion, defined as having 
experienced at least two psychotic symptoms, and when examining the influence of having been 
exposed to at least two or three traumatic events, respectively. In order to strictly predict incident 
psychotic symptoms over the T2-T3 period, the above described analyses excluded all individuals 
with lifetime pre-existing psychotic symptoms as assessed at T2. Accordingly, the remaining 
group of subjects exclusively consisted of individuals who had not developed any psychotic 
symptoms by the time of the T2 assessment, possibly constituting a relatively resilient subgroup. 
However, the interaction remained non-significant also when analyzing the whole cohort (-1.3% 
adjusted difference in risk, 95% CI: -11.1- 8.4, p = 0.782).  
Opposed to what was hypothesized and in contrast to previous findings (Harley, et al., 2010; 
Houston, et al., 2008; Konings, et al., in press), the current analyses did not provide evidence for 
interaction between cannabis use and trauma in increasing psychosis risk. This may be due to 
sampling variation, or alternatively, the relatively long follow-up between T2 and T3 was 
insensitive to this type of analysis. More work in the area of environment-environment 
interactions in predicting psychosis is necessary. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References 
Darroch, J., 1997. Biologic synergism and parallelism. American Journal of 
Epidemiology, 145, 661-8. 
Harley, M., Kelleher, I., Clarke, M., et al, 2010. Cannabis use and childhood trauma 
interact additively to increase the risk of psychotic symptoms in adolescence. 
Psychological medicine, 40, 1627-34. 
Henquet, C., Di Forti, M., Morrison, P., et al, 2008. Gene-environment interplay between 
cannabis and psychosis. Schizophrenia Bulletin, 34, 1111-21. 
Houston, J. E., Murphy, J., Adamson, G., et al, 2008. Childhood sexual abuse, early 
cannabis use, and psychosis: testing an interaction model based on the National 
Comorbidity Survey. Schizophrenia Bulletin, 34, 580-5. 
Konings, M., Stefanis, N., Bakoula, C., et al, in press. Replication in two independent 
population-based samples that childhood trauma interacts with cannabis use on 
psychosis risk. Psychological medicine. 
Kuepper, R., van Os, J., Lieb, R., et al, 2011. Continued cannabis use and risk of 
incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. 
BMJ (Clinical research ed, 342, d738. 
Lieb, R., Isensee, B., von Sydow, K., et al, 2000. The Early Developmental Stages of 
Psychopathology Study (EDSP): a methodological update. European Addiction 
Research, 6, 170-82. 
Robins, L. N., Wing, J., Wittchen, H. U., et al, 1988. The Composite International 
Diagnostic Interview. An epidemiologic Instrument suitable for use in 
conjunction with different diagnostic systems and in different cultures. Archives 
of general psychiatry, 45, 1069-77. 
Wittchen, H. U., Lachner, G., Wunderlich, U., et al, 1998a. Test-retest reliability of the 
computerized DSM-IV version of the Munich-Composite International Diagnostic 
Interview (M-CIDI). Social Psychiatry and Psychiatric Epidemiology, 33, 568-78. 
Wittchen, H. U., Perkonigg, A., Lachner, G., et al, 1998b. Early developmental stages of 
psychopathology study (EDSP): objectives and design. European Addiction 
Research, 4, 18-27. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Interaction between cannabis use and trauma 
T2 cannabis use 
Number with 
psychotic 
symptoms*  
Number without 
psychotic symptoms* 
% Psychotic 
symptoms 
Risk difference Test for overall 
interaction# Unadjusted Adjusted1 
Without trauma      
 
-0.1% adjusted 
difference in risk, 
95%CI: -10.4-
10.4, p = 0.994 
No  127 1137 11.2% 
9.6% 
4.3% 
95%CI: -0.9-9.4, p = 0.105 Yes 51 245 20.8% 
With trauma      
No 35 231 15.2% 
7.6% 
4.2% 
95%CI: 5.3-13.8, p = 0.386 Yes 18 79 22.8% 
Note. Individuals with T2 lifetime psychotic experiences were excluded from the analyses. 
*Assessed at T3 as follows: any rating of ‘present’ on any of the DIAX/M-CIDI core psychosis items. 
1 Adjusted for age, gender, socio-economic status, baseline cannabis use, use of other drugs, and urban environment. 
# Tests whether risk difference in exposure group (‘with trauma’) is significantly greater than risk difference in non-exposure group (‘without trauma’).  
 
 
